Prime Medicine Inc

PRME

3.570USD

+0.330+10.19%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Prime Medicine Inc's Score

Industry at a Glance

Industry Ranking

130 / 392

Overall Ranking

268 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative-

Prime Medicine Inc Highlights

StrengthsRisks

Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering gene editing therapies to patients. It deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. It is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson’s Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.98M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 2.98M.

Fairly Valued

The company’s latest PE is -2.51, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 113.36M shares, increasing 19.45% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 717.68K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 1.24.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

6.464

Target Price

+99.52%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Prime Medicine Inc is 6.83, ranking 202 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.23M, representing a year-over-year increase of 486.12%, while its net profit experienced a year-over-year increase of 3.69%.

Score

Industry at a Glance

Previous score

6.83

Change

0



Financials

5.79

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.69

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.12

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.54

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Prime Medicine Inc is 5.76, ranking 366 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.51, which is -71.52% below the recent high of -0.71 and -476.20% above the recent low of -14.45.

Score

Industry at a Glance

Previous score

5.76

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 130/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Prime Medicine Inc is 7.82, ranking 265 out of 392 in the Biotechnology & Medical Research industry. The average price target is 6.00, with a high of 9.00 and a low of 4.25.

Score

Industry at a Glance

Previous score

7.82

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Prime Medicine Inc is 6.37, ranking 259 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.44 and the support level at 2.95, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.00

Change

0.37

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Prime Medicine Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 62.80%, representing a quarter-over-quarter increase of 32.44%. The largest institutional shareholder is The Vanguard, holding a total of 6.44M shares, representing 3.57% of shares outstanding, with 28.67% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Liu (David R)

20.24M

+0.42%

ARCH Venture Partners

18.49M

+19.61%

Alphabet, Inc.

16.56M

+9.96%

T. Rowe Price Investment Management, Inc.

9.22M

+42.13%

The Vanguard Group, Inc.

Star Investors

4.92M

+35.68%

Newpath Partners LP

6.11M

--

ARK Investment Management LLC

Star Investors

5.48M

+135.84%

BlackRock Institutional Trust Company, N.A.

5.13M

+26.01%

Farallon Capital Management, L.L.C.

4.75M

+533.33%

Gottesdiener (Keith Michael)

4.36M

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Prime Medicine Inc is 3.35, ranking 147 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.75. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Prime Medicine Inc

PRME

6.24 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment